glp-1 drug shortages The shortage is over. What's next for the compounders? Chart: 1 in 8 Americans
Description
This is a huge health crisis since obesity increases chances of diabetes, heart disease, cancer, and lots more
Moreira GV, Azevedo FF, Ribeiro LM, Santos A, Guadagnini D, Gama P, et al
A study in rats (Ramrez et al., 2018) has showed that the DPP4 inhibitor sitagliptin induces a lowering of fatty acid utilization in cardiomyocytes in favour of glucose
What are the benefits of GLP-1 drugs
Ethics approval Approved by London Westminster Research Ethics Committee (REC Reference: 16/LO/1144)
[DOI] [PMC free article] [PubMed] [Google Scholar] 123.Vniant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, et al
